ARTICLE | Company News
Xcyte cancer, infectious news
November 21, 2005 8:00 AM UTC
XCYT discontinued all development of its products and reduced its headcount to eight. Both moves were part of a restructuring that was announced in March (see BioCentury, March 28). XCYT had $26.7 mil...